Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Hammond, P.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Continuous subcutaneous insulin infusion: short-term benefits apparent, long-term benefits speculative

Peter Hammond

Harrogate District Hospital, Lancaster Park Road, HG2 7SX, UK, peter.hammond{at}hhc-tr.northy.nhs.uk

Continuous subcutaneous insulin infusion (CSII) is increasingly used as a means of insulin delivery for those with type 1 diabetes, and has recently been endorsed by NICE for this purpose. CSII improves glycaemic control compared to other intensified insulin regimens, with a small decrease in HbA1C and mean blood glucose, and a larger reduction in glucose fluctuation. This improved control is not associated with an increased risk of hypoglycaemia and CSII probably results in significantly lower rates of severe hypoglycaemia. There is no evidence that those using CSII are at increased risk of diabetic ketoacidosis. CSII is uniquely associated with a small risk of application site infection. CSII has a positive impact on quality of life. There is much less evidence concerning the benefits of CSII in reducing microvascular or macrovascular complication rates. Small studies, mostly from the 1980s, show improvements in markers of early nephropathy, retinopathy progression and neuropathy, but the potential long-term impact of CSII has not been proven. Recently CSII has been used in the management of those Br J Diabetes Vasc Dis 2004;4:104—08 with type 2 diabetes but evidence is lacking with regard to the benefits of using it in this group.

Key Words: continuous subcutaneous insulin infusion (CSII) • type 1 diabetes • type 2 diabetes • microvascular complications • macrovascular complications • glycaemic control • hypoglycaemia.

References

  • Diabetes Control and Complications Trial Research Group: Implementation of treatment protocols in the Diabetes Control and Complications Trial. Diabetes Care 1995;18:361-76.[Abstract]
  • Lauritzen T., Pramming S., Deckert T., Binder C. Pharmacokinetics of continuous subcutaneous insulin infusion. Diabetologia 1983;24:326-9.[Web of Science][Medline] [Order article via Infotrieve]
  • Pickup J., Mattock M., Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ 2002;324:1-6.[Abstract/Free Full Text]
  • Weissberg-Benchell J., Antisdel-Lomaglio J., Seshadri R. Insulin Pump Therapy: A meta-analysis. Diabetes Care 2003;26:1079-87.[Abstract/Free Full Text]
  • Hanaire-Broutin H., Melki V., Bessieres-Lacombe S., Tauber J. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment: a randomized study. Diabetes Care 2000;23:1232-5.[Abstract/Free Full Text]
  • Melki V., Renard E., Lassmann-Vague V. et al. Improvement of HbA1c and blood glucose stability in IDDM patients with lispro insulin analogue in external pumps. Diabetes Care 1998;21:977-81.[Abstract]
  • Renner P., Pfützner A., Trautman M., Harzer O., Sauter K., Landraf R. Insulin lispro in CSII: results of a double-blind crossover study. Diabetes 1997;46:440-3.[Abstract]
  • Zinman B., Tildesley H., Chiasson J-L., Tsui E., Strack T. Insulin lispro in CSII: results of a double-blind crossover study. Diabetes 1997;46:440-3.[Abstract]
  • Bode B., Strange P. Efficacy, safety and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy with type 1 diabetes. Diabetes Care 2001;24:69-72.[Abstract/Free Full Text]
  • Bode BW, Steed RD, Davidson PC Reduction in severe hypoglycaemia with long-term continuous subcutaneous insulin infusion in type 1 diabetes. Diabetes Care 1996;19:324-7.[Abstract]
  • Steindel BS, Roe TR, Costin G., Carlson M., Kaufman FR Continuous subcutaneous insulin infusion (CSII) in children and adolescents with chronic poorly controlled type 1 diabetes mellitus. Diab Res Clin Pract 1995; 27:199-204.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Dudley S., Hammond PJ Safety aspects of continuous subcutaneous insulin infusion (CSII). Diabet Med 2002:19(suppl 2):A50.[CrossRef]
  • Bruttomesso D., Pianta A., Crazzolara D. et al. Continuous subcutaneous insulin infusion (CSII) in the Veneto region: efficacy, acceptability and quality of life. Diabet Med 2002;19:628-34.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Linkeschova R., Raoul M., Bott U., Berger M., Spaul M. Less severe hypoglycaemia, better metabolic control, and improved quality of life in Type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy; an observational study of 100 consecutive patients followed for a mean of 2 years. Diabet Med 2002;19:746-51.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Boland EA, Grey M., Oesterle A., Fredrickson L., Tamborlane WV Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycaemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes. Diabetes Care 1999;22:1779-84.[Abstract/Free Full Text]
  • De Vries JH, Snoek FJ, Kostense PJ, Masurel N., Heine RJ A randomized trial of continuous subcutaneous insulin infusion and intensive injection therapy in type 1 diabetes for patients with long-standing poor control. Diabetes Care 2002;25:2074-80.[Abstract/Free Full Text]
  • Dcct. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol 1998;116:874-86.[Abstract/Free Full Text]
  • The Kroc Collaborative Study Group. Diabetic retinopathy after two years of intensified insulin treatment. Follow-up of the Kroc Collaborative Study. JAMA 1988;260:36-41.
  • Olsen T., Richelsen B., Ehlers N., Beck-Nielsen H. Diabetic retinopathy after 3 years treatment with continuous subcutaneous insulin infusion. Arch Ophthalmol Copenh 1987;65:185-9.
  • Helve E., Laatikainen L., Merenmies L., Koivisto VA Continuous insulin infusion therapy and retinopathy in patients with type 1 diabetes. Acta Endocrinol Copenh 1987;115:313-19.[Abstract/Free Full Text]
  • Bending JJ, Viberti GC, Bilous RW, Keen H. Eight-month correction of hyperglycemia in insulin-dependent diabetes mellitus is associated with a significant and sustained reduction of urinary albumin excretion rates in patients with microalbuminuria. Diabetes 1985;34:69-73.[Web of Science][Medline] [Order article via Infotrieve]
  • Chiasson JL, Ducros F., Poliquin-Hamet M., Lopez D., Lecavalier L., Hamet P. Continuous subcutaneous insulin infusion (Mill-Hill Infuser) versus multiple injections (Medi-Jector) in the treatment of insulin-dependent diabetes mellitus and the effect of metabolic control on microangiopathy. Diabetes Care 1984;7:331-7.[Abstract]
  • Feldt-Rasmussen B., Mathiesen ER, Deckert T. Effect of two years of strict metabolic control on progression of incipient nephropathy in insulindependent diabetes. Lancet 1986;2:1300-04.[CrossRef][Medline] [Order article via Infotrieve]
  • Beck-Nielsen H., Olesen T., Mogensen CE et al. Effect of near normoglycemia for 5 years on progression of early diabetic retinopathy and renal involvement. Diabetes Res 1990;15:185-90.[Medline] [Order article via Infotrieve]
  • Chantelau E., Wichmann P. Pathological proteinuria in patients with insulin-dependent diabetes mellitus: relation to intensive insulin therapy. Exp Clin Endocrinol 1992;99:164-8.[Web of Science][Medline] [Order article via Infotrieve]
  • Dahl-Jorgensen K., Hanssen KF, Kierulf P., Bjoro T., Sandvik L., Aagenaes O. Reduction of urinary albumin excretion after 4 years of continuous subcutaneous insulin infusion in insulin-dependent diabetes mellitus. The Oslo Study. Acta Endocrinol Copenh 1988;117:19-25.[Abstract/Free Full Text]
  • Christensen CK, Christiansen JS, Schmitz A., Christensen T., Hermansen K., Mogensen CE Effect of continuous subcutaneous insulin infusion on kidney function and size in IDDM patients: a 2 year controlled study. J Diabet Complications 1987;1:91-5.[Medline] [Order article via Infotrieve]
  • Beck-Nielsen H., Richelsen B., Mogensen CE et al. Effect of insulin pump treatment for one year on renal function and retinal morphology in patients with IDDM. Diabetes Care 1985;8:585-9.[Abstract]
  • Bangstad HJ, Osterby R., Dahl-Jorgensen K., Berg KJ, Hartmann A., Hanssen KF Improvement of blood glucose control in IDDM patients retards the progression of morphological changes in early diabetic nephropathy. Diabetologia 1994;37:483-90.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Daubresse JC, Henrivaux P., Bailly A., Lemy C., Duchateau A. Long-term management of insulin-treated diabetic patients with continuous subcutaneous insulin infusion. Diabete Metab 1983;9:45-52.[Web of Science][Medline] [Order article via Infotrieve]
  • Bertelsmann FW, Heimans JJ, Van Rooy JC, Dankmeijer HF, Visser SL, Van der Veen EA Peripheral nerve function in patients with painful diabetic neuropathy treated with continuous subcutaneous insulin infusion. J Neuro Neurosurg Psych 1987;50:1337-41.[Abstract/Free Full Text]
  • Boulton AJ, Drury J., Clarke B., Ward JD Continuous subcutaneous insulin infusion in the management of painful diabetic neuropathy. Diabetes Care 1982;5:386-90.[Abstract]
  • Kronert K., Hulser J., Luft D., Stetter T., Eggstein M. Effects of continuous subcutaneous insulin infusion and intensified conventional therapy on peripheral and autonomic nerve dysfunction. J Clin End Metab 1987;64:1219-23.[Abstract/Free Full Text]
  • Fedele D., Bellavere F., Cardone C., Ferri M., Crepaldi G. Improvement of cardiovascular autonomic reflexes after amelioration of metabolic control in insulin-dependent diabetes subjects with severe autonomic neuropathy. Horm Metab Res 1985;17:410-13.[Web of Science][Medline] [Order article via Infotrieve]
  • Lawson P., Trayner I., Rosenstock J. et al. The effect of continuous subcutaneous insulin infusion on serum lipids. Diabetes Met 1984;10:239-44.
  • Lormeau B., Aurousseau MH, Valensi P., Paries J., Attali JR Hyperinsulinemia and hypofibrinolysis: effects of short-term optimized glycemic control with continuous insulin infusion in type II diabetic patients. Metabolism 1997;46:1074-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Turk Z., Flego I., Kerum G. Platelet aggregation in type 1 diabetes without microvascular disease during continuous subcutaneous insulin infusion. Horm Metab Res 1996;28:95-100.[Web of Science][Medline] [Order article via Infotrieve]
  • Jennings AM, Lewis KS, Murdoch S., Talbot JF, Bradley C., Ward JD Randomized trial comparing continuous subcutaneous insulin infusion and conventional insulin therapy in type II diabetic patients poorly controlled with sulfonylureas. Diabetes Care 1991;14:738-44.[Abstract]
  • Raskin P., Bode BW, Marks JB et al. Continuous Subcutaneous Insulin Infusion and Multiple Daily Injection Therapy Are Equally Effective in Type 2 Diabetes. Diabetes Care 2003;26:2598-603.[Abstract/Free Full Text]
  • Ilkova H., Glaser B., Tunckale A., Bagriacik N., Cerasi E. Induction of longterm glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care 1997;20:1353-6.[Abstract]
  • Della Casa L., del Rio G., Glaser B., Cerasi E. Effect of 6-month gliclazide treatment on insulin release and sensitivity to endogenous insulin in NIDDM: role of initial continuous subcutaneous insulin infusion-induced normoglycemia. Am J Med 1991;90:37S-45S.[Medline] [Order article via Infotrieve]
  • Glaser B., Leibovich G., Nesher R., Hartling S., Binder C., Cerasi E. Improved beta-cell function after intensive insulin treatment in severe non-insulin-dependent diabetes. Acta Endocrinol Copenh 1988;118:365-73.[Abstract/Free Full Text]
  • Valensi P., Moura I., Le Magoarou M., Paries J., Perret G., Attali JR Short-term effects of continuous subcutaneous insulin infusion treatment on insulin secretion in non-insulin-dependent overweight patients with poor glycaemic control despite maximal oral anti-diabetic treatment. Diabetes Metab 1997;23:51-7.[Web of Science][Medline] [Order article via Infotrieve]
  • Pouwels MJ, Tack CJ, Hermus AR, Lutterman JA Treatment with intravenous insulin followed by continuous subcutaneous insulin infusion improves glycaemic control in severely resistant Type 2 diabetic patients. Diabet Med 2003;20:76-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

The British Journal of Diabetes & Vascular Disease, Vol. 4, No. 2, 104-108 (2004)
DOI: 10.1177/14746514040040020701
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Hammond, P.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?